TNF and inflammatory bowel disease: About this topic, the European Association for the Study of the Liver (EASL) guidelines suggest that only the etanercept (an anti-TNF agent not used in IBD setting because of inefficacy) has a potential interaction with grazoprevir/elbasvir, which may require a dosage adjustment (European Association for the Study of the Liver, 2017).